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Abstract
Background: Recent evidence indicates that inflammatory parameters could be useful to predict metastasis from
colorectal cancer. However, their roles in predicting chemotherapy response and prognosis in patients with
synchronous colorectal liver metastasis (CLM) are unknown.
Methods: The clinical data and baseline laboratory parameters of 55 patients with synchronous CLM were
retrospectively reviewed. All patients underwent palliative resection of the primary tumor and oxaliplatin-based
chemotherapy. Two indices of systemic inflammation were reviewed—neutrophil-to-lymphocyte ratio (NLR) and
platelet-to-lymphocyte ratio (PLR)—preoperatively and before the second cycle of chemotherapy. Associations
between prognostic variables and tumor response, progression, and survival were investigated.
Results: NLR < 4 and PLR < 150 were correlated with better disease control (p = 0.024 and 0.026, respectively).
In univariate analysis, elevated NLR and PLR were significant prognostic factors for poor overall survival (OS)
and progression-free survival (PFS). In multivariate analysis, PLR (p = 0.027), age (p = 0.018), resection of liver
metastases (p = 0.017), and lactate dehydrogenase level (p = 0.011) were independent predictors of PFS, while
resection of liver metastases was the only independent predictor of OS (p = 0.002). In addition, when patients
were divided into groups according to changes in NLR and/or PLR, reduced NLR and PLR were associated with
improved disease control (p = 0.038 and 0.025, respectively). Normalization of NLR also was associated with
improved PFS.
Conclusions: NLR and PLR are potentially useful clinical biomarkers to predict chemotherapy response in patients with
synchronous CLM. PLR also may be useful to predict PFS in these patients.
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Background
Colorectal cancer (CRC) is the third most common cancer
worldwide and the fifth most common in China [1]. It is
also the fifth most common cause of cancer-related death.
Although there have been remarkable improvements in
the treatment and management of CRC, outcomes remain
poor, with approximately 40% of patients who undergo
curative surgery dying from their disease [2], especially
those with distant metastases.
In patients with synchronous colorectal liver metastasis
(CLM), radical resection is the only curative therapy [3],
which can increase 5-year survival up to 71% [4]. However,
in unresectable or potentially resectable CLM, chemother-
apy is a paramount consideration. Studies have shown that
chemotherapy regimens can downstage 15 to 50% of
patients from unresectable to resectable cancer [5]. How-
ever, there are numerous patients who cannot benefit from
adjuvant chemotherapy, and identifying and developing
biomarkers able to distinguish such patients is important.
Fortunately, several parameters for predicting survival
in patients with CRC have been identified, including such
inflammatory-based prognostic parameters as neutrophil-
to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio
(PLR), white blood cell count, and platelet count [6–9].
NLR, calculated as neutrophil count divided by lymphocyte
count, is the most frequently reported marker and is in-
volved in almost every stage of CRC [6, 10–12]. Increased
NLR is associated with worse outcomes and insensitive
response to adjuvant chemotherapy or radiotherapy [13, 14].
PLR, calculated as platelet count divided by lymphocyte
count, is also gaining attention in some research [8].
It is unclear whether both indices are associated with
chemotherapy response in patients with synchronous CLM
treated with oxaliplatin-based chemotherapy after resection
of primary lesions. Therefore, in this study, we examined
the correlations of NLR and PLR with chemotherapy sensi-
tivity and prognosis in these patients.
Methods
Patient selection, treatment, and follow-up
We retrospectively reviewed a database of patients treated
in the Department of Colorectal Surgery at the Shanghai
Cancer Center from June 2008 to December 2013. Patients
who met the following criteria were selected: (a) ini-
tially diagnosed as having synchronous CLM; (b) eval-
uated as having potentially resectable cancer before
any treatment; (c) Eastern Cooperative Oncology Group
(ECOG) status <2; (d) available and complete clinical
records, including pathologic diagnosis, treatment strat-
egy, follow-up information, and laboratory data; and (e)
treated with first-line chemotherapy. The exclusion criteria
included patients who had either malignant tumors in
other organs or systematic inflammatory or hematologic
disease. Patients with complications from the primary
tumor, such as obstruction or hemorrhage, also were
excluded.
A total of 55 patients were finally included in the
study. All patients underwent R0 resection of the primary
tumor followed by oxaliplatin-based chemotherapy, includ-
ing mFOLFOX6 (folic acid/fluorouracil plus oxaliplatin) or
XELOX (capecitabine plus oxaliplatin). The duration from
surgery to chemotherapy was within 1 month.
Laboratory tests and imaging examinations were per-
formed every 3 months. The Response Evaluation Criteria
in Solid Tumors was applied for evaluation of disease
status. Radical hepatectomy of metastases was conducted
if the patient had reached complete response (CR) or par-
tial response (PR). Four patients who had reached stable
disease (SD) after chemotherapy also underwent radical
hepatectomy, as their metastases had contracted but they
did not meet the baseline criteria of PR.
Parameters evaluated
The following parameters were evaluated: sex, age, number
of liver metastases, CLM resection, and chemotherapy
protocol. Several pathologic parameters, including size,
pathologic subtype, differentiation, location, tumor inva-
sion, nodal status, lymphovascular invasion, perineural
invasion, extranodal tumor deposits, and microsatellite
instability, also were evaluated. Laboratory parameters,
including NLR, PLR, alkaline phosphatase (ALP) level, lac-
tic dehydrogenase (LDH) level, carcinoembryonic antigen
level, and CA199 level, also were assessed.
The number of liver metastases was categorized accord-
ing to the criteria between minor and major lesions [15].
Regarding pathologic diagnosis, expression of MLH1,
MSH2, MLH6, and PMS2 was routinely evaluated. Any
deficiency was considered as deficient mismatch repair.
We used the X-tile Software (http://medicine.yale.edu/
lab/rimm/research/) to determine the cutoff values of
NLR and PLR based on the minimum p values from the
log-rank chi-square statistics (Additional file 1). Finally,
the cutoff values of NLR and PLR were set at 4 and
150, respectively, which were also in accordance with
previous researches [6, 16, 17]. All parameters were
evaluated preoperatively and before the second cycle of
chemotherapy. Other parameters were presented ac-
cording to the normal value range at our hospital.
Statistical analysis
Progression-free survival (PFS) was defined as the duration
from primary tumor resection to disease progression, while
overall survival (OS) was defined as the duration from
surgery to the date of death or the last date of follow-up.
All statistical analyses were performed by using SPSS
version 20.0 (IBM Corporation, Armonk, NY, USA). Fisher’s
exact test was used to compare chemotherapy response
among groups. Survival curves were plotted by using
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the Kaplan-Meier method and analyzed by using the log-
rank test. Univariate and multivariate analyses to identify
prognostic predictors were performed by using Cox pro-
portional hazard models. A p value of <0.05 was consid-
ered as significant in all analyses.
Results
Patient characteristics
All of the patients’ clinicopathologic features are summa-
rized in Table 1. Patients were predominantly male (64%),
and the median age was 59 years. Almost half of the pa-
tients had more than three liver metastases. Regarding
the chemotherapy regimen, 21 patients (38%) received
mFOLFOX6, while 34 (62%) received XELOX. Of these
patients, 12 (22%) underwent radical resection of liver
metastases.
According to the pathologic results, the median max-
imum size of the primary lesion was 4 cm, and almost all
of the lesions (91%) were identified as adenocarcinoma.
Twenty-five patients (45%) suffered from colon cancer,
while 30 (55%) suffered from rectal cancer. Most of the
lesions (98%) reached an invasive depth of T3 to T4 with
local nodal metastasis (80%). Furthermore, lymphovascular
invasion, perineural invasion, and extranodal tumor
deposits were almost evenly distributed, and most of
the patients were proficient mismatch repair.
With regard to laboratory data, 41 patients (75%) had
a low NLR, and 31 (56%) had a low PLR. Other bio-
chemical parameters, such as ALP and LDH levels, were
normal in most of the patients. On the contrary, most of
the patients had elevated serum carcinoembryonic antigen
and CA199 levels.
NLR and PLR with regard to chemotherapy response
Objective chemotherapy response, including CR and PR,
did not differ significantly between groups divided by
preoperative NLR and PLR (p = 0.051 and 0.195, respect-
ively; Table 2). However, disease control, including CR,
PR, and SD, was significantly better in groups with com-
paratively lower preoperative NLR (56–21%, p = 0.024)
and PLR (61–29%, p = 0.026) (Table 2).
Table 1 Characteristic variable
Characteristics Category No. of
patients (%)
Clinical background
Sex Male 35 (64)
Female 20 (36)
Age (years) <60 28 (51)
≥60 27 (49)
Number of liver metastasis ≤3 27 (49)
>3 28 (51)
Liver metastasis resection No 43 (78)
Yes 12 (22)
First-line chemotherapy FOLFOX 21 (38)
XELOX 34 (62)
Surgical pathology
Maximum size (cm) ≤4 29 (53)
>4 26 (47)




Differentiation G1–G2 33 (60)
G3–G4 22 (40)
Location Colon 25 (45)
Rectum 30 (55)
Tumor stage (T) 2 1 (2)
3 13 (24)
4 41 (74)
Nodal status (N) 0 11 (20)
1 19 (35)
2 25 (45)
Lymphovascular invasion No 25 (45)
Yes 30 (55)
Perineural invasion No 28 (51)
Yes 27 (49)
Extranodal tumor deposits No 30 (55)
Yes 25 (45)
MSI status dMMR 4 (7)
pMMR 51 (93)
Blood biochemical test
NLR <4 41 (75)
≥4 14 (25)
PLR <150 31 (56)
≥150 24 (44)
ALP Normal 46 (84)
Elevated 9 (16)
Table 1 Characteristic variable (Continued)
LDH Normal 44 (80)
Elevated 11 (20)
Serum CA199 level Normal 20 (36)
Elevated 35 (64)
Serum CEA level Normal 12 (22)
Elevated 43 (78)
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Prognostic factors
Median OS was significantly longer in patients with
NLR < 4 and PLR < 150, which was 24 to 56 months in
the NLR groups (p = 0.008) and 27 to 56 months in the
PLR groups (p = 0.017) (Fig. 1a, b). Results of median
PFS coincided with those of OS, which was 7 to 23 months
in the NLR groups (p = 0.01) and 8 to 26 months in the
PLR groups (p = 0.002) (Fig. 1c, d).
Tables 3 and 4 show the results of univariate and multi-
variate analyses of various parameters evaluated in this
study. Univariate analysis revealed that number of
metastases >3, no resection of liver metastases, and elevated
NLR and PLR were significantly associated with worse OS.
However, according to multivariate analysis, only resection
of liver metastases was a significant independent prognostic
factor (p = 0.002).
With regard to PFS, the parameters mentioned above,
together with elevated LDH level and patient age <60 years,
correlated with worse PFS. Multivariate analysis revealed
that age (p = 0.018), resection of liver metastases (p =
0.017), LDH level (p = 0.011), and PLR (p = 0.027) were
significant independent prognostic factors.
Normalization of NLR and PLR before cycle 2 and
correlations with PFS and OS
Patients were categorized into three groups as follows:
group 1, patients with NLR < 4 or PLR < 150 at baseline
(n = 41 and 31, respectively); group 2, patients with
Table 2 Chemotherapy response according to NLR and PLR before operation
Response NLR PLR
<4 (N = 41) ≥4 (N = 14) p value <150 (N = 31) ≥150 (N = 24) p value
Objective response rate (CR + PR), % (cases) 20% (8) 0 (0) 0.051 19% (6) 8% (2) 0.195
Disease control rate (CR + PR + SD), % (cases) 56% (23) 21% (3) 0.024* 61% (19) 29% (7) 0.026*
*A p value ≤0.05 was considered statistically significant
Fig. 1 Patients with elevated NLR and PLR had worse prognosis. a, b Patients with higher NLR and PLR tended to have worse overall survival
(p = 0.008 and p = 0.017). c, d Patients with higher NLR and PLR tended to have worse progression-free survival (p = 0.01 and p = 0.002)
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NLR ≥ 4 or PLR ≥ 150 at baseline, which decreased
before cycle 2 of chemotherapy (n = 8 and 11, respectively);
and group 3, patients with a higher NLR or PLR, which did
not decrease before cycle 2 of chemotherapy. As presented
in Table 5, patients with normalization of NLR or PLR
before cycle 2 of chemotherapy showed improved disease
control (p = 0.038 and 0.025, respectively). However, no sig-
nificant change in objective chemotherapy response was
observed, which coincided with the results of preoperative
NLR and PLR.
Finally, we conducted subgroup analysis according to
changes in NLR and PLR between two stages of the
treatment process (Fig. 2a, b). Patients with normalization
of NLR had significantly better PFS than those with a high
NLR that did not decrease (p = 0.002). However, although
a tendency of better PFS was detected in patients with
Table 3 Prognostic factors associated with OS and PFS in univariate analysis
Prognosis variables Overall survival Progression-free survival
p value HR (95% CI) p value HR (95% CI)
Gender, male/female 0.986 1.009 (0.384–2.651) 0.579 1.197 (0.635–2.254)
Age, ≥60/<60 0.109 2.142 (0.844–5.440) 0.007* 0.397 (0.203–0.775)
Number of metastasis, ≥3/<3 0.049* 1.323 (1.011–1.809) 0.015* 2.167 (1.159–4.054)
Liver metastasis resection, yes/no 0.001* 0.028 (0.012–0.049) 0.005* 0.313 (0.138–0.710)
Chemotherapy, FOLFOX/XELOX 0.735 0.855 (0.346–2.113) 0.891 0.925 (0.522–1.759)
Maximum size (cm), ≤4/>4 0.261 2.385 (0.525–10.84) 0.620 1.164 (0.638–2.123)
Pathology, adenocarcinoma/mucinous 0.261 2.385 (0.525–10.84) 0.737 1.225 (0.376–3.993)
Differentiation, G1–G2/G3–G4 0.930 0.958 (0.371–2.478) 0.302 1.386 (0.745–2.580)
Location, colon/rectum 0.421 1.159 (0.809–1.659) 0.446 1.265 (0.691–2.314)
Tumor stage (T)
T2/T3 0.835 6.231 (0.926–52.51) 0.054 7.826 (0.962–63.66)
T2/T4 0.554 1.339 (0.460–4.251) 0.094 2.410 (0.899–4.843)
Nodal status (N)
N0/N1 0.496 0.637 (0.174–2.330) 0.811 0.908 (0.412–2.001)
N0/N2 0.759 0.859 (0.326–2.265) 0.396 0.396 (0.369–1.483)
Lymphovascular invasion, no/yes 0.399 0.683 (0.281–1.658) 0.867 0.950 (0.520–1.735)
Perineural invasion, no/yes 0.289 1.613 (0.667–3.899) 0.064 1.775 (0.967–30257)
Extranodal tumor deposits, no/yes 0.340 1.542 (0.633–3.755) 0.549 1.201 (0.660–2.186)
MSI status, pMMR/MMR 0.371 0.606 (0.202–1.817) 0.542 0.673 (0.189–2.404)
NLR, ≥4/<4 0.013* 3.182 (1.277–7.933) 0.017* 2.284 (1.156–4.498)
PLR, ≥150/<150 0.024* 2.954 (1.155–7.551) 0.002* 2.535 (1.339–4.779)
ALP, elevated/normal 0.905 0.927 (0.267–3.217) 0.374 1.449 (0.640–3.282)
LDH, elevated/normal 0.257 1.810 (0.650–5.041) 0.008 2.673 (1.292–5.528)
Serum CA199 level, elevated/normal 0.343 1.640 (0.590–4.560) 0.700 1.135 (0.596–2.158)
Serum CEA level, elevated/normal 0.487 1.552 (0.450–5.351) 0.669 1.183 (0.548–2.553)
*A p value ≤0.05 was considered statistically significant
Table 4 Prognostic factors associated with OS and PFS in multivariate analysis
Prognosis variables Overall survival Progression-free survival
p value HR (95% CI) p value HR (95% CI)
Age, <60/≥60 0.018* 2.373 (1.162–4.847)
Number of metastasis, <3/≥3 0.781 0.843 (0.251–2.823) 0.582 1.309 (0.501–3.423)
Liver metastasis resection, yes/no 0.002* 0.003 (0.012–0.033) 0.017* 0.180 (0.058–0.554)
NLR, ≥4/<4 0.477 1.511 (0.212–2.064) 0.520 1.334 (0.312–1.801)
PLR, ≥150/<150 0.510 1.447 (0.231–2.070) 0.027* 2.591 (0.166–0.896)
LDH, normal/elevated 0.011* 0.310 (0.125–0.768)
*A p value ≤0.05 was considered statistically significant
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reduced PLR, the difference was not significant (p =
0.329). Moreover, there was no significant difference in
OS (data not shown).
Discussion
To our knowledge, this is the first study to evaluate the
associations of NLR and PLR with prognosis and
chemotherapy response in patients with synchronous
CLM who underwent palliative resection of the pri-
mary tumor followed by oxaliplatin-based chemother-
apy. Our results support the use of NLR and PLR as
markers to predict chemotherapy response and prog-
nosis, which would help to evaluate the possibility of
secondary surgery for CLM as well as to elucidate the
survival rates in such patients.
Immune cells act closely with tumor development, while
NLR reflects systematic inflammation. Several studies have
revealed the prognostic role of NLR in patients with CRC
[6]. Although its mechanism has not been clarified, several
investigations have deduced its close correlations with
interleukin 6, interleukin 8, vascular epidermal growth
factor, and other cytokines, which play important roles
in tumorigenesis [18–20]. However, most studies focused
on the use of NLR as a predictor in advanced CRC.
Vauthey first reported that a high NLR independently
predicted worse OS in patients with CLM treated with
chemotherapy followed by hepatic resection or chemo-
therapy alone [21]. Other studies focusing on unresect-
able CLM have achieved similar results indicating NLR
as an independent predictor of survival [22, 23]. In our
study, we confirmed that a high NLR predicted worse
OS and PFS. However, we did not achieve the same result
in multivariate analysis, which somewhat conflicts with
the studies mentioned above. A possible reason might be
the difference in the study group we enrolled, which was
confined to synchronous CLM with palliative resection of
the primary lesion. However, the close correlation between
NLR and chemotherapy response, i.e., the possibility of
metastasis resection, might cover the statistical difference
in the multivariate analysis model.
The mechanism of PLR in tumorigenesis might be de-
rived from the role of platelets in promoting angiogenesis,
adhesion, and invasion by increasing the production of
vascular epidermal growth factor and transforming growth
Table 5 Chemotherapy response rate according to the alteration in NLR and PLR before the second cycle of treatment
Response NLR PLR
Group 1 (N = 41) Group 2 (N = 8) Group 3 (N = 6) p value Group 1 (N = 31) Group 2 (N = 11) Group 3 (N = 13) p value
Objective response rate
(CR + PR), % (cases)
20% (8) 25% (2) 0 (0) 0.070 19% (6) 18% (2) 0 (0) 0.126
Disease control rate
(CR + PR + SD), % (cases)
56% (23) 38% (3) 0 (0) 0.038* 61% (19) 45% (5) 15% (2) 0.025*
NLR: group 1, <4; group 2, ≥4→ <4; group 3, ≥4→ ≥4. PLR: group 1, <150; group 2, ≥150→ <150; group 3, ≥150→ ≥150
*A p value ≤0.05 was considered statistically significant. (group 2 compared with group 3)
Fig. 2 Changes in PFS with normalization of NLR and PLR. a Patients with normalization of NLR had better PFS (p = 0.002) than those with stable
NLR levels. b PFS of patients with normalization of PLR did not differ (p = 0.329)
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factor-beta in a tumor environment [24]. Meanwhile,
cytokines and chemokines released from platelets facilitate
other immune cells, including neutrophils and lympho-
cytes, to infiltrate into tumor lesions and trigger inflamma-
tory progress [25]. Contrary to the wide study of NLR in
CRC, fewer studies have focused on PLR. Xia demonstrated
that in metastatic CRC, NLR was superior to PLR for pre-
dicting prognosis; in fact, NLR was the only independent
predictor [26]. This finding was confirmed by another study
in which preoperative NLR and derived NLR, but not PLR,
were associated with worse OS and cancer-specific survival
[27]. However, in patients with liver-only colorectal metas-
tases and hepatectomy, Mudan found the reverse result, in
which the prognostic effect of preoperative PLR was su-
perior to that of NLR [28]. In our study, we also found
that patients with a high preoperative PLR had worse
PFS and OS and that only PLR was an independent
predictor of PFS. However, its impact on OS was not
observed, which might also be due to the interaction
with metastasis resection. Overall, we demonstrated a
better prognostic value of PLR than NLR.
NLR and PLR also have been reported as markers of
chemotherapy response. In Clarke’s research, they enrolled
two independent cohorts with unresectable CRC who
received first-line palliative chemotherapy and found
that normalization of NLR after one cycle of chemo-
therapy resulted in improved PFS [24]. Meanwhile, in a
study of patients with advanced or recurrent unresectable
CRC who received oxaliplatin-based combination chemo-
therapy, Kitayama also found better disease control in
those with a low NLR [25]. Our results are in agreement
with these previous studies showing that patients with a
low NLR benefit more from first-line oxaliplatin-based
chemotherapy. Patients with a dramatic decrease in NLR
after one cycle of chemotherapy also demonstrated im-
proved disease control and PFS, as its reduction might
reflect the sensitivity to chemotherapy. Moreover, we
found the same results with regard to PLR. However,
we only found a tendency of improved PFS in those
with normalization of PLR, which might be due to the
limited number of patients in our study.
The current study had several limitations that are
common in retrospective investigations. With an increased
sample size and expanded follow-up, the impact of NLR
and PLR in such patients would be ascertained. In addition,
we did not evaluate the adverse reactions from chemother-
apy, which might have affected the patients’ quality of life
and survival. Finally, we did not consider or standardize the
subsequent therapeutic strategy, which correlated closely
with OS.
Conclusions
In conclusion, our results suggest that preoperative NLR
and PLR and their normalization might be good markers
for better disease control in patients with synchronous
CLM. PLR was better than NLR for predicting PFS in this
study. Based on these findings, we have a better under-
standing of these patients, which may help to guide their
therapeutic strategy.
Additional file
Additional file 1: X-tile plots of NLR and PLR to OS and PFS, respectively.
X-axis represents all cutoff values applied from low to high (left to right) to
define the subsets. Brighter pixels indicate a stronger association between
markers and prognosis. Cutoff values were defined in the brightest pixels
(marked by the bold black dots). A and B. Cutoff values of NLR were 3.9 to
PFS and 3.7 to OS, respectively. C. Cutoff value of PLR to PFS ranged from
about 135 to 220. D. Cutoff value of PLR to OS was 150.1. (TIF 3184.64 kb)
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